Literature DB >> 33865832

RNA therapeutics: From biochemical pharmacology to technology development and clinical applications.

Baitang Ning1, Ai-Ming Yu2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33865832      PMCID： PMC9514225          DOI： 10.1016/j.bcp.2021.114567

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   6.100


× No keyword cloud information.
  28 in total

1.  Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer.

Authors:  Chengzhi Huang; Minjia Wang; Junjiang Wang; Deqing Wu; Yuan Gao; Kaihong Huang; Xueqing Yao
Journal:  Biochem Pharmacol       Date:  2020-12-22       Impact factor: 5.858

2.  S100A16 induces epithelial-mesenchymal transition in human PDAC cells and is a new therapeutic target for pancreatic cancer treatment that synergizes with gemcitabine.

Authors:  Ting Li; Tianyi Ren; Chumei Huang; Yufang Li; Pengfei Yang; Gang Che; Lisi Luo; Yutong Chen; Siqi Peng; Yujing Lin; Linjuan Zeng
Journal:  Biochem Pharmacol       Date:  2020-12-25       Impact factor: 5.858

Review 3.  LncRNA regulation: New frontiers in epigenetic solutions to drug chemoresistance.

Authors:  Ying Zhou; Wen Sun; Zhiyuan Qin; Suhang Guo; Yu Kang; Su Zeng; Lushan Yu
Journal:  Biochem Pharmacol       Date:  2020-09-23       Impact factor: 5.858

Review 4.  Flavonoid display ability to target microRNAs in cancer pathogenesis.

Authors:  Shilpi Singh; Waseem Raza; Shahnaz Parveen; Abha Meena; Suaib Luqman
Journal:  Biochem Pharmacol       Date:  2021-01-08       Impact factor: 5.858

5.  Targeting nucleolin by RNA G-quadruplex-forming motif.

Authors:  Joana Figueiredo; André Miranda; Jéssica Lopes-Nunes; Josué Carvalho; Daniela Alexandre; Salete Valente; Jean-Louis Mergny; Carla Cruz
Journal:  Biochem Pharmacol       Date:  2021-01-16       Impact factor: 5.858

6.  Recognition of nucleolin through interaction with RNA G-quadruplex.

Authors:  Tiago Santos; André Miranda; Maria P C Campello; António Paulo; Gilmar Salgado; Eurico J Cabrita; Carla Cruz
Journal:  Biochem Pharmacol       Date:  2020-08-27       Impact factor: 5.858

7.  RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges.

Authors:  Ai-Ming Yu; Young Hee Choi; Mei-Juan Tu
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

8.  MicroRNA-101 inhibits cadmium-induced angiogenesis by targeting cyclooxygenase-2 in primary human umbilical vein endothelial cells.

Authors:  Lin Che; Zi-Li Wu; Lian-Yun Huang; Jia-Shen Wu; Ze-Bang Du; Jin-Xian Lin; Yan-Hua Su; Xiao-Xuan Chen; Zhong-Ning Lin; Yu-Chun Lin
Journal:  Biochem Pharmacol       Date:  2020-08-09       Impact factor: 5.858

Review 9.  The growth of siRNA-based therapeutics: Updated clinical studies.

Authors:  M May Zhang; Raman Bahal; Theodore P Rasmussen; José E Manautou; Xiao-Bo Zhong
Journal:  Biochem Pharmacol       Date:  2021-01-26       Impact factor: 6.100

Review 10.  Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics.

Authors:  Li Zeng; Dongying Li; Weida Tong; Tieliu Shi; Baitang Ning
Journal:  Biochem Pharmacol       Date:  2021-01-19       Impact factor: 5.858
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.